During pregnancy, placental CRH acts on human myometrium via specific receptors and might play a role in the regulation of myometrial contractility and hence human parturition. The myometrium is the site of production and target of several PGs, which can be activated by cytokines, especially during infection-induced preterm labor. We established primary human myometrial cell cultures that express functional CRH receptors (CRH-R1␣, -R1␤, -R1c, and -R2␤) to investigate the possible regulation of PG production by CRH. We studied the effect of CRH on the two major myometrial PGs, PGE 2 and 6-keto PGF 1␣ . Human CRH was able to partially inhibit basal, interleukin-1␤-stimulated, and oxytocin-stimulated PGE 2 production (56 Ϯ 11%, 45 Ϯ 8%, and 58 Ϯ 6% inhibition, respectively). This effect was blocked by a specific CRH receptor antagonist in a concentration-dependent manner. Furthermore, CRH had no effect on 6-keto PGF 1␣ production, indicating that the CRH inhibitory action does not involve suppression of cyclooxygenase, the enzyme responsible for the production of both PGE 2 and 6-keto-PGF 1␣ . These data further support the view that during pregnancy, CRH may promote myometrial quiescence and might play an important role in the regulation of human labor. (J Clin Endocrinol Metab 84: 2204 -2211 , 1999 
C
URRENT theories suggest that the onset and regulation of parturition in humans are multifactorial. Animal models have proved inadequate to date due to significant differences between human and animal reproductive systems. The last few years, interest has been directed toward placentally derived CRH, the maternal plasma concentrations of which are dramatically increased during the third trimester of human pregnancy (1, 2) , which might act as a placental clock to determine the length of gestation and identify women with threatened preterm labor (3, 4) . The biological function of this placental CRH during pregnancy is still unknown; we have suggested that it might modulate myometrial contractility (5) . In support of this hypothesis was the finding that CRH and its receptors are localized in the human myometrium (6 -8) . These receptors increase their affinity during the latter stages of pregnancy (5) and become functionally linked to the adenylate cyclase system, leading to the increased production of cAMP, a well known myometrial relaxant (9, 10) . At term, there is a reduction in the functional ability of CRH to stimulate cAMP (11) due to 1) a reduction of the number of G s ␣ subunits (12) and 2) an inhibitory action of oxytocin, which activates protein kinase C, leading to phosphorylation and desensitization of the CRH receptor (13) .
Several reports indicate that CRH exerts differential actions on PG production depending on the cell type. It stimulates PG production in placenta, decidua, and fetal membranes in vitro (14) and inhibits interleukin-1␣ (IL-1␣)-induced 6-keto-PGF 1␣ release from bovine aorta endothelial cells and PGE 2 release from human dermal fibroblasts (15) . Although it has not been demonstrated unequivocally, PGs appear to play in important role in the mechanism of labor, and increased PG production is associated with term and preterm labor, especially in the presence of intrauterine infection (16, 17) .
The fetal membranes, especially the amnion, produce predominantly PGE 2 , which appears to be important in the early stages of labor, leading to cervical ripening and dilatation. It has been suggested that increased PG synthesis during labor is the result of increased transcription of the cyclooxygenase-2 (COX-2) gene, which is the inducible form of the enzyme (18) . In humans, COX-2, but not COX-1 (the constitutive form), expression and activity increase at term before the onset of labor in amnion (19) , chorion (20) , and myometrium (21) , but not in decidua (22) . Furthermore, although myometrial COX-1 expression was unaffected in labor, COX-2 expression was reduced in labor in both preterm and term pregnancies (21) . Interestingly, in mice with targeted disruption of the COX-1 gene, the process of labor was delayed, resulting in neonatal death (23) , whereas the targeted disruption of COX-2 produced multiple failures in female reproductive processes, including ovulation, fertilization, implantation, and decidualization (24) . In a range of cell types, including human amnion (25) , decidua (26) , and myometrium (27) , the production of PGs appears to be part of an auto/paracrine system involving various cytokines, and this has been implicated in the initiation of infection-induced preterm human labor (28) .
To investigate further the role of CRH during pregnancy and labor and elucidate in detail its actions in the human myometrium, we have studied its possible involvement in the regulation of PG production from primary human pregnant myometrial cell cultures that express functional CRH receptors.
Subjects and Methods

Experimental subjects
Pregnant myometrial tissue was obtained from women undergoing elective caesarean section for nonmaternal reasons at term before the onset of labor (n ϭ 9). The biopsy was standardized to the upper margin of the lower segment of the uterus in the midline. This provides the closest approximation of the upper segment of the uterus. The patients had no clinical evidence of intrauterine infection. The tissue was immediately processed for cell culture. Ethical approval was obtained from the local ethical committee, and each patient gave informed consent to the study.
Chemicals
Human/rat CRH, ␣-helical CRH-(9 -41), and oxytocin were obtained from Peninsula Laboratories (Merseyside, UK). PGE 2 and 6-keto-PGF 1␣ RIA kits and Amprep C 18 , C 2 minicolumns were obtained from Amersham International (Little Chalfont, UK). Mouse monoclonal vimentin antibody and anti-mouse IgG tetramethyl-rodamine isothiocyanate (TRITC)-conjugated were obtained from Sigma Chemical Co. (Poole, UK). RNeasy plant total ribonucleic acid (RNA) kit for polyadenylated RNA isolation was obtained from QIAGEN (Crawley, UK) Mouse monoclonal muscle actin antibody was obtained from DAKO Corp. (High Wycombe, UK). Synthetic oligonucleotide probes and enzymes were purchased from Life Technologies (Paisley, UK). Antigoat IgGfluorescein isothiocyanate-conjugated and specific CRH receptor antibody (which recognizes both human CRH-R1 and CRH-R2 receptors) were obtained from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). The latter is a goat polyclonal antibody raised against a peptide corresponding to amino acids 425-444 mapping at the C-terminus of the human CRH-R1 precursor. All other chemicals were purchased from Sigma Chemical Co. (Poole, UK). cAMP RIA kits were obtained from New England Nuclear Life Science (Boston, USA). IL-1␤ (recombinant) was obtained from Calbiochem (Nottingham, UK)
Preparation of Myometrial Cell Cultures
Myocytes were prepared by enzymatic dispersion as previously described (13) . Briefly, pieces of myometrium were transferred into DMEM containing collagenase (300 U/mL), deoxyribonuclease (30 U/mL), penicillin (200 U/mL), and streptomycin (200 mg/mL) and incubated at 37 C for 30 min. After filtration and centrifugation, cells were suspended in DMEM containing 10% FCS, penicillin (100 U/mL), streptomycin (100 mg/mL), and fungizone (2.5 g/mL). The cells were kept at 37 C in a humidified atmosphere of 95% air and 5% CO 2 until confluent (ϳ2 weeks). The purity of myometrial muscle cells was assessed by immunocytochemical staining. Mouse antihuman smooth muscle actin-specific monoclonal antibody and peroxidase-conjugated rabbit antimouse antibody were used. Human fibroblast cells and omission of the primary antibody were used as negative controls, whereas frozen myometrial tissue was used as a positive control. To minimize fibroblast contamination we repurified the myocyte preparation 48 h before the experiments using 0.5% trypsin.
RNA extraction and RT-PCR
To investigate the CRH receptor subtypes present in the human pregnant myometrial cells, a RT-PCR technique was used. Different specific primers were used for the CRH-R1 subtypes as previously described (7), whereas for the R2 subtypes the following primers were used. For CRH-R2␤, primers 5Ј-TCCAGTCCCTAACCCCAGCC-3Ј and 5Ј-GGGAATTCCCGGGCCAAGAGGCATGGTTTATTTC-3Ј were used for the first round, and primers 5Ј-CTGGCATGAGGGGTCCCTCAG-3Ј and 5Ј-GGGAATTCCCGGGGCA GGTGGGCGACCGAGGG-3Ј were used for the second round of PCR. For CRH-R2␥, primers 5Ј-CTGT-GCTCAAGCAATCTGCCTAC-3Ј and 5Ј-GGGAATTCCCGGGC-CAAGA GGCATGGTTTATTTC-3Ј were used for the first round, and primers 5Ј-CTTGGCTTCCCCAAGTGCTGAG-3Ј and 5Ј-GGGAATTC-CCGGGGCAGGTGGGCGA CCGAGGG-3Ј were used for the second round of PCR. The products of the second PCR reaction were confirmed using sequence analysis.
Immunofluorescence
Fixed myometrial cells grown on glass slide-flaskettes, washed in phosphate-buffered saline (PBS), and incubated with 3% BSA for 1 h (to block nonspecific binding sites) before incubation with the primary CRH-R antibody for 60 min, which was used at a 1:100 dilution (all dilutions were made in 3% BSA in PBS). After three washes with PBS, specimens were incubated for 30 min with a primary mouse monoclonal actin antibody (1:100) followed by another set of washes as before. Incubation with the first secondary antigoat IgG-fluorescein isothiocyanate-conjugated antibody was carried out for 2 h in the dark, followed by three washes with PBS and addition of the second secondary antimouse IgG tetramethyl-rodamine isothiocyanate (TRITC)-conjugated antibody for 30 min. Specimens were washed thoroughly, and the coverslips were mounted using 90% glycerol-PBS. The results were viewed under fluorescent microscope using appropriate filters.
cAMP production assay and RIA
Human myometrial cells from pregnant women (pregnant myometrial cells) were plated in 24-well plates at an average density of 5 ϫ 10 4 cells/plate and after reaching confluence were incubated in 0.2 mL 10% FCS in DMEM containing 20 mmol/L HEPES, 500 mol/L isobutylmethylxanthine (pH 7.2), and suitable concentrations of human/rat CRH for 10 min at 37 C. Experiments were terminated by the addition of 0.1 mL 0.3 mol/L HCl. Cells were frozen overnight, and cAMP levels were measured in the supernatants using RIA. The sensitivity of the assay was 0.025 pmol, and the precision was: intraassay coefficient of variation (CV), 2.9%; and interassay CV, 9.7%.
PG stimulation assay: determination of 6-keto-PGF 1a and PGE 2
Human pregnant myometrial cells were plated in 12-well plates at an average density of 5 ϫ 10 6 cells/plate and after reaching confluence were incubated in 2 mL 10% FCS in DMEM containing suitable concentrations of the agents tested (CRH, IL-1␤, ␣-helical CRH, and oxytocin) for the time indicated in each experiment. Experiments were terminated by transferring the medium to test tubes. Immediately both PGs were extracted from samples according to the following methods.
PGE 2 .
One milliliter of samples were mixed with 1 mL water-ethanol (1:4) and 20 L glacial acetic acid, vortexed, and left at room temperature for 5 min. After centrifugation at 2500 ϫ g for 2 min, supernatants were applied to Amprep C 18 minicolumns that had been primed with 2 mL 10% ethanol. The columns were washed with 1 mL water and 1 mL hexane. PGE 2 was eluted with 2 ϫ 0.8 mL ethyl acetate and evaporated to dryness under vacuum overnight. Just before the RIA, samples were reconstituted with 100 L PBS, pH 7, containing 0.1% gelatin. Using this method, the recovery of radiolabeled PGE 2 was 91 Ϯ 4%. 1␣ . One milliliter of samples was acidified with 1 mol/L citric acid and applied to Amprep C 2 minicolumns that had been primed with 2 mL methanol and 2 mL water. The columns were washed with 5 mL water, 5 mL 10% ethanol, and 5 mL hexane. 6-Keto-PGF 1␣ was eluted with 5 mL methyl formate, which was then evaporated to dryness under vacuum overnight. Just before the RIA, samples were reconstituted with 1 mL RIA assay buffer. Using this method, the recovery of radiolabeled 6-keto-PGF 1␣ was 88 Ϯ 3%. PGs were measured by RIA. For the PGE 2 assay, antiserum against the methyl oximate derivative was used, which has cross-reactivity with other PGs as follows: PGE 1 , less than 5%; and all other PGs [8-iso-PGE 2 , 19(OH)-PGE 2 , 15-keto-PGE 2 , 6-keto-PGE 1 , PGD 2 , PGF 2␣ , 6-keto-PGF 1␣ ], less than 0.01%. The sensitivity of the assay was 1 pg/tube, and the precision was: intraassay CV, 8.9%; and interassay CV, 11%. For the 6-keto-PGF 1␣ assay, antiserum against 6-keto-PGF 1␣ was used, which has cross-reactivity with other PGs as follows: PGF 1␣ , 1%; PGF 2␣ , 0.8%; PGE 1 /E 2 , 0.5%; and thromboxane B 2 , less than 0.3%. The sensitivity of the assay was 3 pg/tube, and the precision was: intraassay CV, 9.6%; and interassay CV, 13.2%.
6-Keto-PGF
Statistical analysis
Data are shown as the mean Ϯ sem of each measurement. Data were tested for homogeneity, and comparison between group means was performed by one-or two-way ANOVA. P Ͻ 0.05 was considered significant.
Results
Characterization of the CRH receptor subtypes present in primary human pregnant myometrial cells
Using immunofluorescence with a CRH-R1/2-specific antibody, a plasma membrane rich in immunopositive granules was revealed (Fig. 1A) . To confirm the type of cells present in the cultures that were immunopositive for the receptor, double staining was performed on the same specimens for CRH-R1/2 and actin (specific smooth muscle cell marker).
As shown in Fig. 1B , the cells were positive for actin, suggesting that our primary cultured human pregnant myometrial smooth muscle cells express specific membrane-bound CRH receptors. In preliminary experiments, HEK293 cells stably transfected with CRH-R1␣. CRH-R1␤ or CRH-R2␤ receptors were used as positive controls, whereas untransfected 293 cells were used as negative controls (data not shown). Omission of the anti-CRH receptor antibody was also used as a negative control (data not shown).
However, because the specific CRH-R antibody used recognizes both human CRH-R1 and CRH-R2 receptors and cannot distinguish between different receptor subtypes, we employed specific primers and RT-PCR followed by sequencing to characterize in detail the specific receptor subtypes. Four known receptor subtypes were identified: CRH-R1␣, CRH-R1␤, CRH-R1c, and CRH-R2␤ (Fig. 2a) . No CRH-R2␥ messenger RNA (mRNA) was identified, consistent with the idea that this receptor is confined to the brain only. Interestingly, CRH-R2␣ mRNA was not found in these cell cultures, a receptor subtype that was present in biopsies from pregnant, but not nonpregnant, myometrium. Because RNA was isolated from the cells on the day of confluence (on day 13 Ϯ 2), we investigated the effect of the culture period on the CRH-R subtype profile. Identical CRH-R subtypes were found in the cells from the 5th day up to the 10th week of culture (4th passage).
Furthermore, the cultured myometrial cells were able to produce cAMP in response to increasing concentrations of CRH (Fig. 2b) . CRH caused a dose-dependent increase in adenylate cyclase activity, with a threshold of 50 -100 pmol/L CRH and a maximal increase (350 Ϯ 76% increase in basal) at a concentration of 100 nmol/L. No significant variation was observed between different preparations of myometrial cells.
Effect of IL-1␤ on PG production
Exposure of cultured human pregnant myometrial cells to IL-1␤ in a concentration range of 1-100 ng/mL stimulated the release of PGE 2 and PGI 2 , as measured by its stable metabolite 6-keto-PGF 1␣ ; in contrast, IL-1␤ in a concentration range of 0.01-0.5 ng/mL had no effect (data not shown). The concentration of IL-1␤ that produced maximal PG release was 10 ng/mL and was used in subsequent experiments. No significant variation was observed between the preparations of myometrial cells tested (n ϭ 9). The IL-1␤-stimulated release of PGs was also time dependent (Fig. 3 ). IL-1␤ was able to stimulate a significant increase in PGs after 8 -12 h of incubation, achieving maximal responses after 18 h (200 Ϯ 45% above basal levels). In time-matched untreated controls, PG production was also time dependent, and the variation in PG production over time was 24 Ϯ 5%. Furthermore, in our culture system PGE 2 was the major PG released, with 6-keto-PGF 1␣ concentrations being 4 times less than those of PGE 2 ( Table 1) .
Effect of CRH on basal and IL-1␤-stimulated PG release
In human myometrial cells, CRH was able to inhibit both basal and IL-1␤-stimulated PGE 2 production (56 Ϯ 11% inhibition of basal and 45 Ϯ 8% inhibition of IL-1␤-stimulated; . 4a ). In contrast, CRH had no effect on basal or IL-1␤-stimulated levels of 6-keto-PGF 1␣ production (Fig. 4b) . In subsequent experiments it was found that the CRH effect on PGE 2 production was rapid, reaching maximal inhibition within the first 30 min of incubation, and was persistent for up to 18 h (Fig. 5a ). It was also found to be concentration dependent, with maximum inhibition observed at a CRH concentration range of 1-10 nmol/L (Fig. 5b) . Interestingly, at high concentrations (100 nmol/L), CRH was able to induce a small, but significant (22 Ϯ 7%), increase in PGE 2 production.
The CRH effect appeared to be mediated via specific CRH receptors in myometrial cells, as it was diminished or completely abolished when the specific CRH receptor antagonist ␣-helical CRH-(9 -41) in a concentration range of 100 nmol/ L-1 mol/L was coincubated with CRH (Fig. 6) .
Effect of CRH on oxytocin-stimulated PGE 2 release
Oxytocin in a concentration range of 0.1-10 nmol/L was able to stimulate PGE 2 release in human pregnant myometrial cells (data not shown). PGE 2 levels were increased by 200 Ϯ 30% above basal after 30-min incubation with 10 nmol/L oxytocin (Fig. 7) . When human CRH (10 nmol/L) was coincubated with oxytocin (10 nmol/L), no significant increase in basal PGE 2 levels was observed. FIG. 2 . a, Nested PCR amplification of the various human CRH receptor subtypes from mRNA extracted from primary human myometrial cell cultures. Specific primers for each receptor subtype mRNA were used as described in Materials and Methods. PCR products were resolved on 1.2% agarose gel and DNA stained with ethidium bromide. I) Primer sets were designed to amplify either the 5Ј-end or the 3Ј-end of the CRH-R1␤ receptor subtype mRNA. For the 5Ј-end of the mRNA, lane 1 shows amplification of a 850-bp fragment, and for the 3Ј-end, lane 2 shows amplification of a 520-bp fragment compared with the DNA size marker. Lane 3 shows amplification of a 1261-bp fragment, which corresponds to the full-length CRH-R1␣ receptor mRNA. II) Lane 1 shows amplification of 1261-and 1141-bp fragments, which correspond to the CRH-R1␣ and CRH-R1d receptor mRNAs. III) Lane 1 shows amplification of a 1350-bp fragment of the CRH-R2␤ receptor mRNA. The identities of the fragments were confirmed by nucleotide sequencing. b, CRH-induced cAMP production from human pregnant myometrial cells. Cells were incubated with increasing concentrations of CRH for 10 min at 37 C. Results are representative of six separate cell culture preparations. Each point is the mean Ϯ SEM of four estimates. *, P Ͻ 0.05 compared to basal (100%, untreated) values.
Discussion
The functions of CRH in the human myometrium are currently under investigation. We originally reported that human myometrium expresses multiple CRH receptor isoforms (8) and have subsequently provided evidence for differential expression of these isoforms between pregnant and nonpregnant myometria (7). This was confirmed by an independent laboratory, which also showed that there is CRH receptor regional distribution in the human myometrium and that CRH-R1 mRNA in the lower uterine segment was decreased during pregnancy and increased significantly in both preterm and term labor, but remained unchanged in the fundus (29) . Nevertheless, these observations suggest that CRH may have multiple actions mediated by distinct isoforms. In this study we investigated the possible involvement of CRH in the regulation of PG production from human myometrium, as it is well established that CRH can stimulate PG production in placenta, decidua, and fetal membranes in vitro (14) . The myometrium can be the site of production and the target of several PGs activated by cytokines, especially during infection-induced preterm labor. Initially, we established primary human myometrial cell cultures, and using immunofluorescence and RT-PCR we identified that the CRH receptor subtypes expressed in the smooth muscle cells are the CRH-R1␣, -R1␤, -R1c, and -R2␤. We also showed that these receptors are functional, as upon stimulation with CRH, they can activate adenylate cyclase and cAMP production, consistent with previous observations (9) . However, at present and because of the lack of receptor subtype-specific antibodies, it is not possible to identify the relative receptor subtype expression. Furthermore, these cell cultures do not contain mRNA for CRH-R2␣, although the tissues of origin (pregnant myometrial tissue obtained from women at term undergoing elective caesarean section) were found to be positive for that particular CRH-R subtype mRNA. This finding suggests that maternal factors that are components of the pregnant environment may play a major role in the regulation of this subtype expression. However, only studies on the CRH-R2 promoter will help to elucidate in detail this phenomenon. These findings indicate the limitations of experiments performed in cells cultured for long periods of time and the difficulties present in extrapolating and interpreting the results from these studies to the in vivo phenomena. One explanation is that our cultures contain predominantly smooth muscle cells during the culture period, and the type 2␣ receptor in vivo may be expressed in another cell type, such as uterine fibroblasts. Using immunofluorescence in pregnant myometrium tissue sections, we have previously reported that CRH receptors (R1 and/or R2) are present in uterine fibroblasts (7) . This phenomenon is currently under investigation. In this study we restricted our experiments to relatively pure cultures of myocytes to enable the data to be interpreted more easily. Consistent with previous reports (28), IL-1␤ was able induce the secretion of PGE 2 and PGI 2 , as measured by its stable metabolite 6-keto-PGF 1␣ , from myometrial cells in a time-and concentration-dependent manner. We studied the effect of CRH on these two major myometrial PGs. Interestingly, the myometrium is the only tissue from the feto-maternal membranes that has the capacity to secrete appreciable amounts of 6-keto-PGF 1␣ (30) . Although CRH at physiological concentrations had no effect on basal or IL-1␤-stimulated 6-keto-PGF 1␣ , it exerted a complex effect on basal and IL-1␤-stimulated PGE 2 production. In a CRH concentration range of 1-10 nmol/L, which is around the physiological concentration of CRH at term, it was able to suppress both basal and IL-1␤-stimulated PGE 2 production. This is a novel finding, which indicates that CRH may play a role in the regulation of myometrial quiescence. It is well known that a number of enzymes are involved in PG biosynthesis from the principal precursor arachidonic acid, COX, which converts arachidonic acid into cyclic endoperoxide (PGG 2 ), which, in turn, is converted rapidly into PGH 2 by the action of peroxidase. It is now thought that the same protein is responsible for both reactions and is called PG endoperoxide H synthetase (COX). These intermediates can be further metabolized to PGs and thromboxanes by the actions of various isomerases. PGI 2 is derived by the action of prostacyclin isomerase, whereas PGE 2 is the result of the action of endoperoxide isomerase on PGH 2 . Our data suggest that the action of CRH on myometrial cells is not targeted on the COX or prostacyclin isomerase expression/activity, as the PGI 2 pathway remains unaffected by CRH action. It is possible that CRH is able to diminish the activity or expression of endoperoxide isomerase, which is the only enzyme responsible for PGE 2 generation. Another possibility is that CRH might influence the rate of PGE 2 metabolism to PGF 2␣ , 13,14-dihydro-15-oxo-PGF 2␣ , or 13,14-dihydro-15-oxo-PGE 2 by modulating the corresponding enzymes, such as the PG-9-oxo-reductase, that are present in the myometrium (35) .
The exact intracellular signaling pathway by which IL-1␤ can stimulate PG release in human myometrial cells is not yet fully understood. Stimulation of high affinity IL-1 receptors leads to increased levels of cAMP, possibly by the induction of one or more of the components of the adenylate cyclase system (31) . This action of IL-1␤ on PG production could be potentiated by protein kinase C activation (32) . Also, in amnion the stimulatory action of IL-1␤ on PGE 2 production is attenuated by down-regulation of protein kinase C (33) . In contrast, in human decidual cells basal PGE 2 production is stimulated by protein kinase C activation, whereas IL-1␤-stimulated PGE 2 synthesis is not affected by down-regulation of this enzyme, suggesting that IL-1␤ and protein kinase C stimulate PGE 2 production via different mechanisms (34) .
At present, the exact pathway or receptor subtype by which CRH partially inhibits PGE 2 release is not known. It is possible that activation of the adenylate cyclase-cAMPdependent protein kinase is involved, as we have shown that CRH can activate this pathway in human myometrial cells. It has been demonstrated that in amnion, activation of this enzyme attenuates the stimulatory effect of epidermal growth factor (36) and oxytocin (37) on PGE 2 production, whereas in human chorion and decidual cells, activation of adenylate cyclase results in enhanced stimulatory action of IL-1␤, epidermal growth factor, and phorbol 12-myristate 13-acetate on PG production (38) . These observations suggest that activation of the adenylate cyclase-cAMP-dependent protein kinase pathway can have effects on PG production that are specific with respect to tissue source and presence of other activators/inhibitors.
Interestingly, at higher concentrations CRH induced a small, but significant, stimulation of PGE 2 release. These data are in agreement with our previous observations, where we described a small, but significant, stimulatory effect (20 Ϯ 6% increase from basal) of CRH on PGE 2 production from membranes prepared from human myometrial biopsies at term (9) . Although this might represent a pure pharmacological effect, it is also possible that within the myometrial cells different CRH-R subtypes mediate diverse and complex cellular responses and actions, such as activation of phospholipase A 2 activation, which leads to increased arachidonic acid production and increased PGE 2 biosynthesis. However, specific CRH-R subtype antagonists will be needed to test this hypothesis.
We have also shown that in human pregnant myometrial cells oxytocin in a concentration range of 0.1-10 nmol/L is able to stimulate PGE 2 release. It is well accepted that in the human myometrium oxytocin activates the phospholipase C-inositol triphosphate-protein kinase C pathway (39, 13) , and this action of oxytocin on myometrial PGE 2 release is consistent with the hypothesis that in some intrauterine tissues, such as the amnion, activation of protein kinase C can stimulate PGE 2 production (40). The observation that CRH is able to inhibit the oxytocin-induced PGE 2 stimulation suggests that at term before the onset of human labor CRH might act as a signal that exerts a general inhibitory effect on PGE 2 production independent of which pathway is activated.
Although both stimulatory (via generation of PG from the fetal membranes) and inhibitory (via stimulation of adenylate cyclase) actions of myometrial contractility have been proposed (41) (42) (43) , the role of CRH during pregnancy remains unknown. The presence of multiple CRH receptor subtypes in the human pregnant myometrium suggests distinct functional roles for each receptor during pregnancy and raises the possibility of multiple roles for CRH and/or related peptides. It is attractive to speculate that some CRH receptor isoforms may be responsible for the maintenance of myometrial quiescence via generation of cAMP and/or in- hibition of myometrial PGE 2 production. At term, inhibition of the biological activity of these receptor subtypes may enable CRH to exert different actions and therefore to play a central role in the control of uterine contractility and the mechanism of labor (13) .
